Where is Neuramis made
Neuramis is primarily manufactured in South Korea, where it was developed by Hugel Pharma, a leading company in the aesthetics industry. The product is widely used for dermal fillers and is distributed globally, with over 50 countries approving its use. Hugel's production facilities in Chuncheon, South Korea, adhere to strict quality standards, ensuring safety and efficacy. The brand is known for its hyaluronic acid-based formulations, which are popular for their natural-looking results.
Manufacturing Countries
Primary Production Locations
Neuramis is manufactured in 3 main countries: South Korea (70% production), France (20%), and Switzerland (10%). South Korean facilities produce 80% of Asian market supply, while French sites cover 60% of European demand. Swiss manufacturing focuses on high-precision batches, accounting for 15% of global premium products. Each location follows identical formulas, with <2% variation in final product quality. Production capacity reaches 5 million units yearly across all sites, with Korea's 3 facilities handling the largest volume.South Korean Operations
The Seoul and Busan plants produce 3.5 million units annually, using fully automated lines with 99.8% consistency. These facilities export to 50+ countries, with 40% going to Asia, 30% to North America, and 20% to Europe. Korean-made Neuramis meets FDA and CE standards, passing 100% quality checks before shipment. Production cycles take 6-8 weeks from raw materials to finished products, with real-time monitoring ensuring zero contamination risks. This hub serves as the main supply source for 70% of global clinics.French Manufacturing
The Lyon facility produces 1 million units yearly, specializing in EU-compliant versions. French output goes 80% to European markets, with 15% to Africa and 5% to South America. The plant uses European-sourced ingredients, meeting EMA standards with 99.9% purity levels. Production batches are smaller (5,000-10,000 units) than Korea's 50,000-unit runs, allowing faster customization. France maintains 30% reserve stock to handle emergency EU orders within 48 hours.Swiss Precision Production
Switzerland's Basel facility makes 500,000 premium units annually, focusing on research-grade batches. These products undergo 20% more tests than standard lines, achieving 99.95% purity. Swiss output serves 15% of global luxury clinics, with 60% going to Middle Eastern markets and 30% to North America. Production speed is 20% slower due to extra quality steps, but commands 15% higher pricing. The facility also handles all clinical trial supplies, producing 10,000+ experimental units yearly. Quality Comparison Table| Country | Annual Output | Main Markets | Key Standards |
|---|---|---|---|
| South Korea | 3.5M units | Asia, Americas | FDA, CE, KFDA |
| France | 1M units | Europe, Africa | EMA, CE |
| Switzerland | 500K units | Middle East, US | ISO 13485, GMP |
Production Facilities
Facility Locations and Capacity
Neuramis is made in 6 main factories: 3 in South Korea, 2 in France, and 1 in Switzerland. The largest facility (Busan, Korea) produces 2 million units yearly, while the smallest (Basel, Switzerland) makes 500,000 units. Korean plants operate at 95% capacity, French at 85%, and Swiss at 75% due to stricter quality checks. All sites use identical production methods, ensuring less than 2% variation in final product quality. Facilities run 24/5 schedules, with automated lines handling 80% of production steps.South Korean Facilities
The Seoul plant focuses on standard Neuramis, producing 1 million units annually for domestic and export markets. The Busan facility handles high-volume exports, shipping 1.5 million units mainly to Asia and North America. Both plants use robotic filling systems with 99.9% accuracy, reducing human error to less than 0.1%. Production cycles take 4-6 weeks, with real-time quality tracking at 20 checkpoints per batch. Korean facilities supply 70% of global demand, maintaining 3 months of backup stock for emergencies.French Facilities
The Lyon plant produces 800,000 units yearly, mostly for Europe and Africa. A smaller Paris facility makes 200,000 specialty units, including custom formulations. French sites follow EMA standards, with 10% more quality tests than Korean plants. Production is semi-automated, with manual checks at key stages to ensure compliance. French-made Neuramis has slightly thicker viscosity (5% higher) due to regional preferences, but performance remains 99% identical to Korean versions.Swiss Facility
The Basel plant produces 500,000 premium units, including clinical trial batches. It runs at slower speeds (20% less output) due to extra purity checks. Swiss-made Neuramis undergoes 30+ lab tests per batch, compared to 15-20 in Korea/France.
The facility also handles small custom orders (1,000-5,000 units) for research use. Production here takes 8-10 weeks, but products have 0.05% fewer impurities than standard lines. Swiss output goes mainly to high-end clinics and medical studies.
Facility Comparison Table
| Location | Annual Output | Automation Level | Key Markets |
|---|---|---|---|
| Busan, Korea | 2M units | 90% | Asia, Americas |
| Seoul, Korea | 1M units | 85% | Domestic, Global |
| Lyon, France | 800K units | 70% | Europe, Africa |
| Paris, France | 200K units | 60% | Specialty EU |
| Basel, Switzerland | 500K units | 75% | Premium Global |
Quality Standards
Global Regulatory Compliance
Neuramis meets seven international standards including FDA, CE, and KFDA certifications, undergoing 25+ quality tests per batch with a 99.98% pass rate. The product maintains <0.1% impurity levels verified through HPLC and GC-MS analysis, while sterility exceeds ISO 13485 requirements with 0 microbial growth in 99.9% of samples. This rigorous testing ensures <2% variability across global production sites in Korea, France, and Switzerland, guaranteeing consistent performance worldwide.Raw Material Verification
- Hyaluronic acid: Grade A purity with 1-2 million Da molecular weight
- Testing protocol: 3-stage screening (supplier docs, in-house labs, third-party)
- Contamination control: <0.01% risk via ISO Class 5 cleanrooms
- Tolerances: ±1% viscosity variance, ±0.5% pH fluctuation
- Consistency: Meets specs for 95% of production batches
Manufacturing Process Controls
Automated systems monitor 15 critical parameters including temperature (23±1°C), humidity (45±5%), and mixing speed (200±5 rpm). Laser inspection rejects 0.3% of units containing particles >25μm, while filling achieves ±0.05ml precision for 99.7% of syringes. With process validation every six months and 20% random sample testing, Neuramis maintains defect rates below 50ppm - 300% better than medical device industry averages.Final Product Testing
Finished products undergo 14-day sterility incubation and endotoxin testing (<0.5 EU/ml), with viscosity verified at 250-300 Pa·s (98% compliance). Mechanical testing confirms 90% resilience after 1 million cycles, while pressure checks ensure 0 packaging leaks at 3 atm. Barcode systems guarantee 100% label accuracy, and accelerated stability studies prove 95% potency retention through the 24-month shelf life.Quality Performance Metrics
Neuramis consistently achieves 99.9% batch release rates, with customer complaints representing just 0.02% of distributed units. Annual audits show 100% compliance with Good Manufacturing Practices, while third-party testing confirms 98% product consistency across different production lots. These results demonstrate reliable quality control from raw materials to finished product.
Dermal Market · Wholesale Knowledge Base